NCT06701656 - JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS- Cohort C: Bevacizumab | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

February 26, 2025

Primary Completion Date

November 26, 2027

Study Completion Date

February 8, 2028

Conditions

Acute Respiratory Distress Syndrome (ARDS)ARDSARDS (Acute Respiratory Distress Syndrome)Acute Respiratory Distress Syndrome

Interventions

DRUG

Cohort C: bevacizumab

Administered as a single IV dose of 500 mg on Day 1

DRUG

Cohort C: placebo

Administered as a single IV dose of placebo on Day 1

Trial Locations (16)

10467

RECRUITING

Montefiore Hospital - Moses Campus, The Bronx

90806-1701

RECRUITING

Long Beach Memorial Medical Center, Long Beach

92868-3201

RECRUITING

University of California Irvine Medical Center, Orange

20010-3017

RECRUITING

MedStar Washington Hospital Center, Washington D.C.

34209-4617

RECRUITING

Nova Clinical Research, Bradenton

83712-6241

RECRUITING

St. Luke's Boise Medical Center, Boise

61637-0001

RECRUITING

OSF Saint Francis Medical Center-, Peoria

01805-0001

RECRUITING

Lahey Hospital and Medical Center, Burlington

55905-0001

RECRUITING

Mayo Clinic, Rochester

89502-1576

WITHDRAWN

Renown Institute for Heart & Vascular Health, Reno

08901-1928

RECRUITING

Robert Wood Johnson Medical School, New Brunswick

27599-0001

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

27705-3875

RECRUITING

Durham VA Medical Center, Durham

43608-2603

RECRUITING

Mercy Health - St. Vincent Medical Center, Toledo

73104-3609

RECRUITING

The University of Oklahoma Health Sciences Center, Oklahoma City

97239-3011

RECRUITING

Oregon Health and Science University, Portland